Skip to content

Study · Randomized controlled trial · n = 166 · 1995

8 results

Decrease in symptoms, blood loss and uterine size with nafarelin acetate before abdominal hysterectomy: a placebo-controlled, double-blind study.

Ylikorkala O, Tiitinen A, Hulkko S, Kivinen S, Nummi S

Human reproduction (Oxford, England)1 Jun 1995Cited by 13 (Europe PMC)

PMID7593517 (opens in a new tab)PepBankPUB-07593517
Publisher pageAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women undergoing hysterectomy, operative duration was similar after nafarelin and placebo.

    In plain wordsIn women undergoing hysterectomy, surgery duration was similar after nafarelin and placebo.

    Peptide
    Nafarelin
    Outcome
    No significant changeOperative duration
    Study

    n = 166

    Comparator
    Placebo
    Outcome group
    Surgical outcomes · Reproductive and sexual health
    Studied dose
    200 micrograms twice daily · nasal spray · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    This, however, gave no objective benefit during surgery (similar operative durations and blood losses).
    2 context sentences
    Summary · context
    we randomized 188 pre-menopausal women with uterine fibroids (n = 111), menometrorrhagia (n = 58) or pelvic pain (n = 19) to receive either nafarelin (200 micrograms twice daily as a nasal spray) or a placebo for 3 months before abdominal hysterectomy.
    Summary · context
    The data analysis could be performed in 166 women, of whom 107 received nafarelin and 59 a placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women undergoing hysterectomy, operative blood loss was similar after nafarelin and placebo.

    In plain wordsIn women undergoing hysterectomy, blood loss during surgery was similar after nafarelin and placebo.

    Peptide
    Nafarelin
    Outcome
    No significant changeOperative blood loss
    Study

    n = 166

    Comparator
    Placebo
    Outcome group
    Surgical outcomes · Reproductive and sexual health
    Studied dose
    200 micrograms twice daily · nasal spray · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    This, however, gave no objective benefit during surgery (similar operative durations and blood losses).
    2 context sentences
    Summary · context
    we randomized 188 pre-menopausal women with uterine fibroids (n = 111), menometrorrhagia (n = 58) or pelvic pain (n = 19) to receive either nafarelin (200 micrograms twice daily as a nasal spray) or a placebo for 3 months before abdominal hysterectomy.
    Summary · context
    The data analysis could be performed in 166 women, of whom 107 received nafarelin and 59 a placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women undergoing hysterectomy, uterine weight was lower after nafarelin than placebo: 255.5 +/- 12.6 versus 346.2 +/- 35.7 g (P = 0.029).

    In plain wordsIn women undergoing hysterectomy, womb weight was lower after nafarelin than placebo.

    Peptide
    Nafarelin
    Outcome
    DecreaseUterine weight
    Study

    n = 166

    Comparator
    Placebo
    Outcome group
    Uterine size · Reproductive and sexual health
    Studied dose
    200 micrograms twice daily · nasal spray · 3 monthsAs given in this study (human).

    Measurements

    Mean uterine weight
    255.5 g
    nafarelin
    Standard deviation of uterine weight
    12.6 g
    nafarelin
    Mean uterine weight
    346.2 g
    placebo
    Standard deviation of uterine weight
    35.7 g
    placebo
    P value
    0.029
    nafarelin vs placebo

    Source sentences

    Summary
    The uteri from patients treated with nafarelin (255.5 +/- 12.6 g, mean +/- SD) were significantly lighter (P = 0.029) than those from patients treated with a placebo (346.2 +/- 35.7 g).
    2 context sentences
    Summary · context
    we randomized 188 pre-menopausal women with uterine fibroids (n = 111), menometrorrhagia (n = 58) or pelvic pain (n = 19) to receive either nafarelin (200 micrograms twice daily as a nasal spray) or a placebo for 3 months before abdominal hysterectomy.
    Summary · context
    The data analysis could be performed in 166 women, of whom 107 received nafarelin and 59 a placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women undergoing hysterectomy, proliferative endometrium occurred in 56% with nafarelin versus 41% with placebo.

    In plain wordsIn women undergoing hysterectomy, proliferative womb lining occurred in 56% with nafarelin versus 41% with placebo.

    Peptide
    Nafarelin
    Outcome
    IncreaseProliferative endometrium
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Tissue histology · Reproductive and sexual health
    Studied dose
    200 micrograms twice daily · nasal spray · 3 monthsAs given in this study (human).

    Measurements

    Patients with proliferative endometrium
    56%
    nafarelin
    Patients with proliferative endometrium
    41%
    placebo

    Source sentences

    Summary
    The endometrium was proliferative in 56% and showed mild hyperplastic features in 10% of patients given nafarelin, whereas the respective figures for the placebo group were 41 and 0%.
    2 context sentences
    Summary · context
    we randomized 188 pre-menopausal women with uterine fibroids (n = 111), menometrorrhagia (n = 58) or pelvic pain (n = 19) to receive either nafarelin (200 micrograms twice daily as a nasal spray) or a placebo for 3 months before abdominal hysterectomy.
    Summary · context
    The data analysis could be performed in 166 women, of whom 107 received nafarelin and 59 a placebo.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women undergoing hysterectomy, mild endometrial hyperplastic features occurred in 10% with nafarelin versus 0% with placebo.

    In plain wordsIn women undergoing hysterectomy, mildly thickened womb lining occurred in 10% with nafarelin versus 0% with placebo.

    Peptide
    Nafarelin
    Outcome
    IncreaseMild endometrial hyperplasia
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Tissue histology · Reproductive and sexual health
    Studied dose
    200 micrograms twice daily · nasal spray · 3 monthsAs given in this study (human).

    Measurements

    Patients with mild hyperplastic endometrial features
    10%
    nafarelin
    Patients with mild hyperplastic endometrial features
    0%
    placebo

    Source sentences

    Summary
    The endometrium was proliferative in 56% and showed mild hyperplastic features in 10% of patients given nafarelin, whereas the respective figures for the placebo group were 41 and 0%.
    2 context sentences
    Summary · context
    we randomized 188 pre-menopausal women with uterine fibroids (n = 111), menometrorrhagia (n = 58) or pelvic pain (n = 19) to receive either nafarelin (200 micrograms twice daily as a nasal spray) or a placebo for 3 months before abdominal hysterectomy.
    Summary · context
    The data analysis could be performed in 166 women, of whom 107 received nafarelin and 59 a placebo.
  6. 06HumanRandomized controlled trialSafety outcome

    In women awaiting hysterectomy, hot flushes occurred in 61% with nafarelin versus 35% with placebo.

    In plain wordsIn women awaiting hysterectomy, hot flushes occurred in 61% with nafarelin versus 35% with placebo.

    Peptide
    Nafarelin
    Outcome
    IncreaseHot flushes
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    200 micrograms twice daily · nasal spray · 3 monthsAs given in this study (human).

    Measurements

    Patients reporting hot flushes
    61%
    nafarelin
    Patients reporting hot flushes
    35%
    placebo

    Source sentences

    Summary
    Hot flushes were the most common side-effects, being reported by 61% in the nafarelin group and 35% in the placebo group.
    2 context sentences
    Summary · context
    we randomized 188 pre-menopausal women with uterine fibroids (n = 111), menometrorrhagia (n = 58) or pelvic pain (n = 19) to receive either nafarelin (200 micrograms twice daily as a nasal spray) or a placebo for 3 months before abdominal hysterectomy.
    Summary · context
    The data analysis could be performed in 166 women, of whom 107 received nafarelin and 59 a placebo.
  7. 07HumanNon-randomized trialEfficacy outcome

    In women awaiting hysterectomy, nafarelin increased blood haemoglobin by 5.5 g/l.

    In plain wordsIn women awaiting hysterectomy, nafarelin increased blood haemoglobin by 5.5 g/l.

    Peptide
    Nafarelin
    Outcome
    IncreaseBlood haemoglobin
    Study

    n = 107

    Outcome group
    Blood haemoglobin · Reproductive and sexual health
    Studied dose
    200 micrograms twice daily · nasal spray · 3 monthsAs given in this study (human).

    Measurements

    Blood haemoglobin rise
    5.5 g/l
    nafarelin

    Source sentences

    Summary
    Nafarelin led to a rise in blood haemoglobin (5.5 g/l) and to a decrease in uterine volume (23.7%).
    2 context sentences
    Summary · context
    we randomized 188 pre-menopausal women with uterine fibroids (n = 111), menometrorrhagia (n = 58) or pelvic pain (n = 19) to receive either nafarelin (200 micrograms twice daily as a nasal spray) or a placebo for 3 months before abdominal hysterectomy.
    Summary · context
    The data analysis could be performed in 166 women, of whom 107 received nafarelin and 59 a placebo.
  8. 08HumanNon-randomized trialEfficacy outcome

    In women awaiting hysterectomy, nafarelin decreased uterine volume by 23.7%.

    In plain wordsIn women awaiting hysterectomy, nafarelin decreased womb volume by 23.7%.

    Peptide
    Nafarelin
    Outcome
    DecreaseUterine volume
    Study

    n = 107

    Outcome group
    Uterine size · Reproductive and sexual health
    Studied dose
    200 micrograms twice daily · nasal spray · 3 monthsAs given in this study (human).

    Measurements

    Uterine volume decrease
    23.7%
    nafarelin

    Source sentences

    Summary
    Nafarelin led to a rise in blood haemoglobin (5.5 g/l) and to a decrease in uterine volume (23.7%).
    2 context sentences
    Summary · context
    we randomized 188 pre-menopausal women with uterine fibroids (n = 111), menometrorrhagia (n = 58) or pelvic pain (n = 19) to receive either nafarelin (200 micrograms twice daily as a nasal spray) or a placebo for 3 months before abdominal hysterectomy.
    Summary · context
    The data analysis could be performed in 166 women, of whom 107 received nafarelin and 59 a placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.